BioCentury | Jul 29, 2020

Enthera’s €28M series A latest sign of growth for Italy’s biotech ecosystem

U.S. and European investors are backing the largest-ever series A financing for an Italian biotech, autoimmune play Enthera s.r.l. Enthera raised €28 million ($32.8 million) in the round, which was led by existing investor Sofinnova...
BioCentury | May 15, 2020

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

Adding to a steady drip of biotechs testing U.S. public markets, ADC Therapeutics became the latest to climb on its trading debut after pricing an upsized IPO. ADC Therapeutics S.A. (NYSE:ADCT) rose $10.65 (56%) to...
BioCentury | Jun 28, 2018
Translation in Brief

Conformist nanobodies

A University of Zurich team in collaboration with Roche has figured out how to make fully synthetic nanobodies that can bind to membrane proteins in specific conformations -- simultaneously opening up new target space for...
BioCentury | Jun 28, 2018
Distillery Techniques

Assays and screens; chemistry; drug platforms

TECHNOLOGY: Binding assays; tool compounds; antibody scaffolds A method for generating and screening synthetic nanobodies could be used to identify compounds that bind membrane proteins in a conformation-specific manner, for use as therapeutics or research...
BioCentury | Jun 20, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus aureus infection. Screening of a CRISPR single-guide RNA (sgRNA) library in a human lung lymphoblast cell line expressing CRISPR-associated...
BioCentury | May 11, 2018
Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
BioCentury | Jul 18, 2017
Financial News

Enterin raises $12.7M in series A

Neurodegenerative company Enterin Inc. (Philadelphia, Pa.) raised $12.7 million in a series A round led by New Ventures III. Undisclosed existing private investors also participated. Enterin is developing lead candidate ENT-01 to treat constipation associated...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
BioCentury | May 13, 2017
Emerging Company Profile

Dialing down dynamin

...a gene therapy, while Valerion Therapeutics LLC ’s VAL-0620 is a fusion protein of an equilibrative nucleoside transporter 2 (ENT2)-dependent...
BioCentury | Mar 23, 2017
Translation in Brief

High-altitude hypoxia

Researchers have uncovered a pathway in human blood that helps cells cope with low oxygen levels at high altitudes, and have shown in mice that a target in pathway -- solute carrier family 29 nucleoside...
Items per page:
1 - 10 of 59